European Journal of Cancer
Volume 39, Issue 6 , Pages 822-828 , April 2003

Dihydropyrimidine dehydrogenase circadian rhythm in mouse liver: comparison between enzyme activity and gene expression

  • B Porsin

      Affiliations

    • Oncopharmacology Unit, Centre Antoine Lacassagne, 33, Avenue de Valombrose, 06189 Nice Cedex 2, France
    • ,
  • J.-L Formento

      Affiliations

    • Oncopharmacology Unit, Centre Antoine Lacassagne, 33, Avenue de Valombrose, 06189 Nice Cedex 2, France
    • ,
  • E Filipski

      Affiliations

    • Laboratoire “Rythmes Biologiques et chronothérapeutiques”, Université Paris Sud, Institut du Cancer et d'Immunogénétique, Hôpital Paul Brousse, 14-16 av. P-V Couturier, 94800 Villejuif, France
    • ,
  • M.-C Etienne

      Affiliations

    • Oncopharmacology Unit, Centre Antoine Lacassagne, 33, Avenue de Valombrose, 06189 Nice Cedex 2, France
    • ,
  • M Francoual

      Affiliations

    • Oncopharmacology Unit, Centre Antoine Lacassagne, 33, Avenue de Valombrose, 06189 Nice Cedex 2, France
    • ,
  • N Renée

      Affiliations

    • Oncopharmacology Unit, Centre Antoine Lacassagne, 33, Avenue de Valombrose, 06189 Nice Cedex 2, France
    • ,
  • N Magné

      Affiliations

    • Oncopharmacology Unit, Centre Antoine Lacassagne, 33, Avenue de Valombrose, 06189 Nice Cedex 2, France
    • ,
  • F Lévi

      Affiliations

    • Laboratoire “Rythmes Biologiques et chronothérapeutiques”, Université Paris Sud, Institut du Cancer et d'Immunogénétique, Hôpital Paul Brousse, 14-16 av. P-V Couturier, 94800 Villejuif, France
    • ,
  • G Milano

      Affiliations

    • Oncopharmacology Unit, Centre Antoine Lacassagne, 33, Avenue de Valombrose, 06189 Nice Cedex 2, France
    • Corresponding Author InformationCorresponding author. Tel.: +33-4-9203-1553; fax: +33-4-9381-7131

Received 17 May 2002 ,Revised 15 August 2002 ,Accepted 1 October 2002.

References 

  1. Diasio RB, Harris BE. Clinical pharmacology of 5-fluorouracil. Clin. Pharmacokinet. 1989;16:215–237
  2. Fleming R, Milano G, Thyss A, et al.  Correlation between dihydropyrimidine dehydrogenase activity in peripheral mononuclear cells and systemic clearance of fluorouracil in cancer patient. Cancer Res. 1992;52:2899–2902
  3. Fleming RA, Milano G, Gaspard MH, et al.  Dihydropyrimidine deshydrogenase activity in cancer patients. Eur. J. Cancer. 1993;29:740–744
  4. Beck A, Etienne MC, Cheradame S, et al.  A role for dihydropyrimidine dehydrogenase and thymidylate synthase in tumor sensitivity to fluorouracil. Eur. J. Cancer. 1994;30:1517–1522
  5. Etienne MC, Cheradame S, Fischel JL, et al.  Response to fluorouracil therapy in cancer patients (the role of tumoral dihydropyrimidine dehydrogenase activity). J. Clin. Oncol. 1995;13:1663–1670
  6. Milano G, Etienne MC, Pierrefite V, Barberi-Heyob M, Deporte-Fety R, Renée N. Dihydropyrimidine dehydrogenase deficiency and fluorouracil related toxicity. Br. J. Cancer. 1999;79:627–630
  7. Grem JL, Danenberg KD, Behan K, et al.  Thymidine kinase, thymidylate synthase and dihydropyrimidine dehydrogenase profiles of cell lines of the National Cancer Institute's Anticancer drug screen. Clin. Cancer Res. 2001;7:999–1009
  8. Harris BE, Song R, He YJ, Soong SJ, Diasio RB. Circadian rhythm of rat liver dihydropyrimidine dehydrogenase, possible relevance to fluoropyrimidine chemotherapy. Biochem. Pharmacol. 1988;37:4759–4762
  9. Harris BE, Song R, Soong SJ, Diasio RB. Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluororuracil levels with evidence for circadian variation of enzyme activity and plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infusion. Cancer Res. 1990;50:197–201
  10. Grem JL, Yee LK, Venzon DJ, Takimoto CH, Allegra CJ. Inter-and intra-individual variation in dihydropyrimidine dehydrogenase activity in peripheral blood mononuclear cells. Cancer Chemother. Pharmacol. 1997;40:117–125
  11. Balsalobre A, Damiola F, Schibler U. A serum shock induces circadian gene expression in mammalian tissue culture cells. Cell. 1998;93:929–937
  12. Tanaka-Nozaki M, Onda M, Tanaka N, Kato S. Variations in 5-fluorouracil concentrations of colorectal tissues as compared with dihydropyrimidine dehydrogenase (DPD) enzyme activities and DPD messenger RNA levels. Clin. Cancer Res. 2001;7:2783–2787
  13. Uetake H, Ichikawa W, Takechi T, Fukushima M, Nihei Z, Sugihara K. Relationship between intratumoral dihydropyrimidine dehydrogenase activity and gene expression in human colorectal cancer. Clin. Cancer Res. 1999;5:2836–2839
  14. Castillo L, Milano G, Santini J, Demard F, Pierrefite V. Analysis of retinoic acid receptor β expression in normal and malignant laryngeal mucosa by a sensitive and routine applicable reverse transcription-polymerase chain reaction-linked immunosorbent assay method. Clin. Cancer Res. 1997;3:2137–2142
  15. Petit E, Milano G, Levi F, Thyss A, Bailleul F, Schneider M. Circadian rhythm varying plasma concentration of 5-fluorouracil during a five day continuous venous infusion at constant rate in cancer patients. Cancer Res. 1988;48:1976–1979
  16. Zhang R, Lu Z, Liu T, Soong SJ, Diasio RB. Relationship between circadian-dependent toxicity of 5-fluorodeoxyuridine and circadian rhythms of pyrimidine enzymes (possible relevance to fluoropyrimidine chemotherapy). Cancer Res. 1993;53:2816–2822
  17. Metzger G, Massari C, Etienne MC, et al.  Spontaneous or imposed circadian changes in plasma concentrations of 5-fluorouracil coadministered with folinic acid and oxaliplatin relationship with mucosal toxicity in patients with cancer. Clin. Pharmacol. Ther. 1994;56:190–201
  18. Lévi F, Zidani R, Vannetzel JM, et al.  Chronomodulated versus fixed infusion rate delivery of ambulatory chemotherapy with oxaliplatin, 5-fluorouracil and folinic acid in patients with colorectal cancer metastases. A randomized multiinstitutional trial. J. Natl. Cancer Inst. 1994;86:1608–1617
  19. Lévi F, Zidani R, Misset JL  for the International Organization for Cancer Chronotherapy . Randomized multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer. Lancet. 1997;350:681–686
  20. Curé H, Chevalier V, Adenis A, et al.  Phase II trial of chronomodulated infusion of high-dose fluorouracil and l-folinic acid in previously untreated patients with metastatic colorectal cancer. J. Clin. Oncol. 2002;20:1175–1181
  21. Naguib FNM, Soong SJ, El Kouni MH. Circadian rhythm of orotate phosphoribosyltransferase, pyrimidine nucleoside phosphorylases and dihydrouracil dehydrogenase in mouse liver. Possible relevance to chemotherapy with 5-fluoropyrimidines. Biochem. Pharmacol. 1993;45:667–673
  22. Haus E, Lakatua D, Swoyer J, Sackett-Lundeen L. Chronobiology in hematology and immunology. Am. J. Anat. 1983;168:467–517
  23. Tampellini M, Filipski E, Liu X-H, Li X-M, François E, Lévi F. Circadian rhythm in docetaxel tolerability and efficacy in mice. Cancer Res. 1998;58:3896–3904
  24. Shiotani T, Weber G. Purification and properties of dihydropyrimidine dehydrogenase from rat liver. J. Biol. Chem. 1981;256:219–224
  25. Queiroz-Claret C, Queiroz O. Multiple levels in the control of rhythms in enzyme synthesis and activity by circadian clocks (recent trends). Chronobiol. Int. 1990;7:25–33
  26. Dunlap J. An end in the beginning. Science. 1998;280:1548–1549
  27. Gekakis N, Staknis D, Nguyen HB, et al.  Role of clock protein in the mammalian circadian mechanism. Science. 1998;280:1564–1567
  28. Foulkes N, Borjigin J, Snyder SH, Sassone-Corsi P. Rhythmic transcription (the molecular basis of circadian melatonin synthesis). Trends Neurosci. 1997;20:487–492
  29. Lakin-Thomas PL. Circadian rhythms, new functions for old clock genes?. Trends Genet. 2000;16:135–142
  30. Torra IP, Tsibulsky V, Delaunay F, et al.  Circadian and glucocorticoid regulation of Rev-erbalpha expression in liver. Endocrinology. 2000;141:3799–3806
  31. Collie-Duguid ESR, Johnston SJ, Powrie RH, et al.  Cloning and initial characterization of the human DPYD gene promoter. Biochem. Biophys. Res. Comm. 2000;271:28–35

PII: S0959-8049(02)00598-1

doi: 10.1016/S0959-8049(02)00598-1

European Journal of Cancer
Volume 39, Issue 6 , Pages 822-828 , April 2003

Article Tools

* Image Usage & Resolution